Results 81 to 90 of about 1,097,318 (312)

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte   +10 more
wiley   +1 more source

Autophagy in liver diseases

open access: yesJournal of Hepatology, 2010
Autophagy, or cellular self-digestion, is a cellular pathway crucial for development, differentiation, survival, and homeostasis. Its implication in human diseases has been highlighted during the last decade. Recent data show that autophagy is involved in major fields of hepatology.
François Durand   +11 more
openaire   +3 more sources

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis

open access: yesHepatology Communications, 2018
Preimplantation factor (PIF) is an evolutionary conserved peptide secreted by viable embryos which promotes maternal tolerance without immune suppression. Synthetic PIF (sPIF) replicates native peptide activity.
Christopher B. O’Brien   +8 more
doaj   +1 more source

Loss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment

open access: yesMolecular Oncology, EarlyView.
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho   +11 more
wiley   +1 more source

Seroprevalence of CMV infection in patients with active ulcerative colitis and underlying factors of pathogenicity

open access: yesBMC Infectious Diseases
Background Cytomegalovirus (CMV) infection has garnered increasing attention in the context of active ulcerative colitis (UC), a chronic IBD, characterized by periods of remission and relapse.
Farahnaz Joukar   +7 more
doaj   +1 more source

Thrombocytopenia in Liver Disease [PDF]

open access: yesCanadian Journal of Gastroenterology and Hepatology, 1999
Moderate thrombocytopenia is a frequent finding in cirrhosis of the liver and well tolerated in most instances. The pathophysiology of thrombocytopenia in liver disease has long been associated with the concept of hypersplenism, where portal hypertension was thought to cause pooling and sequestration of all corpuscular elements of the blood ...
openaire   +4 more sources

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

open access: yesMolecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy